Chicago — May 2, 2016 — Brainlab, a global leader in medical technology, marks “Brain Tumor Awareness Month” in May, actively participating in patient-oriented events while driving R&D and technology advancements. Brainlab technology is in use in over 4,375 hospitals worldwide and the company is dedicated to improving access to and consistency of treatments for brain tumor patients.
Today, more than 700,000 people in the United States are living with a brain tumor with nearly 78,000 new cases of primary brain tumor diagnoses expected this year alone. Metastatic brain cancer occurs when a primary cancer spreads to the brain and is five times more common than primary brain tumors. Worldwide, brain tumors make up 1.8% of all cancer incidents according to the International Agency for Research on Cancer (IARC).
“Fighting cancer takes very careful application of best practice and the best technology to provide the best possible treatment,” said Stefan Vilsmeier, President and CEO, Brainlab. “Increasingly, the cancer treatment of the future is going to be a combination of different treatments based on careful analysis of all the information available for each patient.”
Today, surgery and radiosurgery are viewed as effective options to treat brain tumors. Brainlab offers information-driven technology to enable enhanced decision-making. Surgical navigation supports less invasive and more precise tumor resections compared with non-navigated techniques. Stereotactic radiosurgery helps maximize tumor control while limiting toxicity to healthy tissue and typically can be delivered in a 30-minute painless treatment. Software like Adaptive Hybrid Surgery allows clinicians to carefully balance the risks of both surgical and radiosurgical treatments, allowing different combinations of both techniques.
“Ultimately, at Brainlab, we are constantly working to get patients to adjust to the idea of living with their cancer, while still enjoying the things that matter to them, which is different for each patient. The treatment should never be worse than the cancer,” concludes Vilsmeier.
Brainlab employees will participate in #WearGrayDay on May 12th. Brainlab employees also took part in the American Brain Tumor Association’s signature fundraising event, the BT5K Breakthrough for Brain Tumors Run & Walk, helping drive awareness and raise over $700,000. The BT5K is held in cities coast to coast throughout the year to help the American Brain Tumor Association fund desperately needed brain tumor research, patient programs and support services.
See Stefan Vilsmeier discussing technology for fighting brain tumors on YouTube https://youtu.be/DF8rVtiDVGQ
Together we, treat, fight, win. Navigate brain cancer treatment at Brainlab.org.
Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.
Core products center on information-guided surgery, radiosurgery, precision radiation therapy, digital operating room integration, and information and knowledge exchange. Brainlab technology powers treatments in radiosurgery and radiotherapy as well as numerous surgical fields including neurosurgery, orthopedic, ENT, CMF, spine and trauma.
Privately held since its formation in 1989, Brainlab has over 9,000 systems installed in about 100 countries. Brainlab employs 1,300 people in 19 offices worldwide, including 385 research & development engineers, who form a crucial part of the product development team.
To learn more, visit www.brainlab.com.